Literature DB >> 18256405

Melanoma complicating treatment with natalizumab for multiple sclerosis.

John T Mullen, Timothy K Vartanian, Michael B Atkins.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18256405     DOI: 10.1056/NEJMc0706103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  35 in total

1.  Hydrocephalus during natalizumab treatment.

Authors:  Chiara Zecca; Claudio Städler; Claudio Gobbi
Journal:  Neurol Sci       Date:  2010-05-08       Impact factor: 3.307

Review 2.  Natalizumab (Tysabri).

Authors:  D T Selewski; G V Shah; B M Segal; P A Rajdev; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2010-08-05       Impact factor: 3.825

Review 3.  [Therapeutic monoclonal antibodies in clinical neurology].

Authors:  M Buttmann; H Wiendl
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

4.  Natalizumab: Increased Vigilance is Required in Treating Patients with Multiple Sclerosis.

Authors:  Michael K Racke; Olaf Stüve
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

5.  Innovative monoclonal antibody therapies in multiple sclerosis.

Authors:  Ralf A Linker; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

6.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Ozgür Yaldizli; Norman Putzki
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

7.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

Review 8.  [Choice of early and escalation treatment options for multiple sclerosis].

Authors:  R A Linker; B C Kieseier
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

9.  Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis.

Authors:  Azza Ismail; Julie Kemp; Basil Sharrack
Journal:  J Neurol       Date:  2009-07-16       Impact factor: 4.849

Review 10.  Treatment of multiple sclerosis: role of natalizumab.

Authors:  Giancarlo Comi
Journal:  Neurol Sci       Date:  2009-10       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.